Sulfuric Acid

Sulfuric Acid

SCHEMBL5787947

C[N+](C)(C)CC(O)CO.O=S(=O)([O-])O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CYP51cyp51Acyp51c

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC22A16 Q86VW1 1/20 0.45
MAPT P10636 1/20 0.40
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35
CPT2 P23786 1/20 0.33
CPT1A P50416 1/20 0.33
BBOX1 O75936 1/20 0.32
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM1 P11229 1/20 0.30
TBXA2R P21731 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL15820210 0.93 SLC22A16 (0.46) SLC22A16MAPTTP53SMN1; SMN2ALDH1A1
Sulfuric Acid SCHEMBL17273303 0.91 MAPT (0.43) SLC22A16MAPTTP53SMN1; SMN2ALDH1A1
Trifluoromethanesulfonic Acid SCHEMBL28133078 0.84 SLC22A16 (0.39) SLC22A16MAPTTP53SMN1; SMN2
SCHEMBL9819526 0.83
SCHEMBL35947 0.83
SCHEMBL6667882 0.83
Bicarbonate SCHEMBL17888806 0.81 SLC22A16 (0.60) SLC22A16MAPTSMN1; SMN2ALDH1A1TSHR
Sulfuric Acid SCHEMBL8508246 0.80 SLC22A16 (0.43) SLC22A16MAPTALDH1A1TSHRMEN1
Hydrochloric Acid SCHEMBL9819532 0.80 MAPT (0.50) SLC22A16MAPTSMN1; SMN2ALDH1A1TSHR
Bromide SCHEMBL8408095 0.80 LMNA (0.47) SLC22A16MAPTSMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160206992-A1 GAS SWEETENING SOLVENTS CONTAINING QUATERNARY AMMONIUM SALTS DOW GLOBAL TECHNOLOGIES LLC 2016-07-21 US claimed
EP-3038736-A1 GAS SWEETENING SOLVENTS CONTAINING QUATERNARY AMMONIUM SALTS Dow Global Technologies LLC (US) 2016-07-06 EP claimed
US-20150335547-A1 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS COLGATE-PALMOLIVE COMPANY (US) 2015-11-26 US claimed
EP-2934469-A2 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS Colgate-Palmolive Company (US) 2015-10-28 EP claimed
WO-2014098871-A2 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS COLGATE-PALMOLIVE COMPANY (US) 2014-06-26 WO claimed
EP-1086072-B1 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF UNIV MICHIGAN STATE (US) 2006-10-18 EP claimed
EP-1086072-A4 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF UNIV MICHIGAN STATE (US) 2004-12-22 EP claimed
EP-1086072-A1 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF MICHIGAN STATE UNIVERSITY (US) 2001-03-28 EP claimed
US-6084131-A Process for the preparation of protected dihydroxypropyl trialkylammonium salts and derivatives thereof BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2000-07-04 US claimed
WO-1999062863-A1 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF MICHIGAN STATE UNIVERSITY (US) 1999-12-09 WO claimed
US-10449483-B2 Gas sweetening solvents containing quaternary ammonium salts DOW GLOBAL TECHNOLOGIES LLC (US) 2019-10-22 US disclosed
US-20160206992-A1 GAS SWEETENING SOLVENTS CONTAINING QUATERNARY AMMONIUM SALTS DOW GLOBAL TECHNOLOGIES LLC 2016-07-21 US disclosed
EP-3038736-A1 GAS SWEETENING SOLVENTS CONTAINING QUATERNARY AMMONIUM SALTS Dow Global Technologies LLC (US) 2016-07-06 EP disclosed
EP-1086072-B1 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF UNIV MICHIGAN STATE (US) 2006-10-18 EP disclosed
EP-1086072-A4 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF UNIV MICHIGAN STATE (US) 2004-12-22 EP disclosed
EP-1086072-A1 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF MICHIGAN STATE UNIVERSITY (US) 2001-03-28 EP disclosed
US-6084131-A Process for the preparation of protected dihydroxypropyl trialkylammonium salts and derivatives thereof BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 2000-07-04 US disclosed
WO-1999062863-A1 PROCESS FOR THE PREPARATION OF PROTECTED DIHYDROXYPROPYL TRIALKYLAMMONIUM SALTS AND DERIVATIVES THEREOF MICHIGAN STATE UNIVERSITY (US) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335547-A1 ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS MCOLN3, TAS2R39, TAS2R40 SLC22A16 712/4885MAPT 1305/4885TP53 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.